Adjuvant gemcitabine after resection of pancreatic cancer without significant difference in overall survival: a retrospective cohort study

International guidelines recommend adjuvant chemotherapy after resection of pancreatic adenocarcinoma. The administration of gemcitabine has become part of the interdisciplinary treatment concept. The authors aim to prove whether the benefit in overall survival (OS) reported in randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Katrin, Büchler, Peter, Henne-Bruns, Doris, Manzini, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328665/
https://www.ncbi.nlm.nih.gov/pubmed/37427179
http://dx.doi.org/10.1097/MS9.0000000000000854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328665/
https://www.ncbi.nlm.nih.gov/pubmed/37427179
http://dx.doi.org/10.1097/MS9.0000000000000854

Ejemplares similares